
Hidradenitis Suppurativa patients in Active group had statistically and practically meaningful +22.5% difference in HiSCR response compared to placebo group at week 16 vs baseline


Illustrative

Active group share of HiSCR responders vs **Placebo** group when the baseline data are compared to the follow-up data (at week 16).



Hidradenitis Suppurativa patients in Active group had statistically and practically meaningful +22.5% difference in HiSCR response compared to placebo group at week 16 vs baseline

Illustrative




Active group share of HiSCR responders vs Placebo group when the baseline data are compared to the follow-up data (at week 16).

Hidradenitis Suppurativa patients in Active group had statistically and practically meaningful +22.5% difference in HiSCR response compared to placebo group at week 16 vs baseline

Active group share of HiSCR responders vs **Placebo** group when the baseline data are compared to the follow-up data (at week 16).

Illustrative



of Abscesses for Active and Placebo Group

